ICMS Registry Reaches 750 Cases

The ICMS Treatment Registry has reached 750 stem cell patient cases being tracked.

The 750 patients have all received autologous adult stem cell treatments and have been tracked in the ICMS Treatment Registry, a secure, web-based data collection system that tracks patient-reported outcomes and complications from patient surveys and interviews at 3, 6, and 12 months, and 2, 3, 4, 5, 10 and 20 years after the treatment.  The rate of complication from these treatments has been less than 2%, and no severe adverse events have been reported. 

While the ICMS has collected tremendous amounts of data, the organization is adamant about maintaining the privacy of the patients and the confidentiality of the treatment protocols. The data stored in the Registry, including the processes by which the cells are collected and administered, as well as specific patient outcomes, are secure, private and available only to the clinic, the patient and select reviewers of the ICMS. These reviewers, in turn, only access Registry data to evaluate protocols and audit patient outcomes, and are bound by strict confidentiality and nondisclosure agreements. Individual members of the ICMS have no access to either patient data or the confidential processes that clinics utilize to treat patients. The ICMS does not publish outcomes from specific clinics. The ICMS does, however, publish all unadjudicated complaints and findings resulting from investigations on reported severe adverse events.

To read the full press release pleas follow the link.

Click HERE to learn more about the ICMS Treatment Registry.